Intravenously administered recombinant human type VII collagen derived from Chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice

Journal of Investigative Dermatology

Volumn 135, Issue 12, 2015, Pages 3060-3067

  Hou, Yingping ^a   Guey, Lin T ^b   Wu, Timothy ^a   Gao, Robert ^a   Cogan, Jon ^a   Wang, Xinyi ^a   Hong, Elizabeth ^a   Ning, Weihuang Vivian ^a   Keene, Douglas ^c   Liu, Nan ^b   Huang, Yan ^b   Kaftan, Craig ^b   Tangarone, Bruce ^b   Quinones Garcia, Igor ^b   Uitto, Jouni ^d   Francone, Omar L ^b   Woodley, David T ^a   Chen, Mei ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SHIRE   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; DERMATOLOGICAL AGENT; FIBRONECTIN; PROTEINASE; RECOMBINANT TYPE VII COLLAGEN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLISTER; CELL MIGRATION; CHO CELL LINE; CONTROLLED STUDY; DERMIS; DISULFIDE BOND; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; EPIDERMIS; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN FIBROBLAST; SKIN FRAGILITY; SKIN INJURY; ANIMAL; CELL CULTURE; CELL MOTION; CHEMISTRY; CRICETULUS; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; ANIMALS, NEWBORN; CELL MOVEMENT; CELLS, CULTURED; CHO CELLS; COLLAGEN TYPE VII; CRICETULUS; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HUMANS; INJECTIONS, INTRAVENOUS; PHENOTYPE; RECOMBINANT PROTEINS;

EID: 84948720611     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.291     Document Type: Article

References (47)

1. Albrecht-Buehler G. (1977). The phagokinetic tracks of 3T3 cells. Cell 11: 395-404
2. Batorova A, High KA, Gringeri A. (2010). Special lectures in haemophilia management. Haemophilia 5: 22-8
3. Beutler E. (2004). Enzyme replacement in Gaucher disease. PLoS Med e21 118-21
4. Boyce ST, Ham RG. (1983). Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serumfree serial culture. J Invest Dermatol 81: 33S-44S
5. Burgeson RE. (1993). Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 101: 252-5
6. Burgeson RE, Lunstrum GP, Rokosova B, et al. (1990). The structure and function of type VII collagen. Ann NY Acad Sci 580: 32-43
7. Chen M, Costa FK, Lindvay CR, et al. (2002). The recombinant expression of fulllength type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa. J Biol Chem 277: 2118-24
8. Chen M, Kasahara N, Keene DR, et al. (2002). Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32: 670-5
9. Chen M, Marinkovich MP, Jones JJ, et al. (1999). NC1 domain of type VII collagen binds to the beta 3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol 112: 177-83
10. Chen M, Marinkovich MP, Veis A, et al. (1997). Interactions of the aminoterminus noncollagenous domain (NC1) of type VII collagen with extracellular matrix components: a potential role in epidermal-dermal adherence in human skin. J Biol Chem 272: 14516-22
11. Chen M, Petersen PJ, Hai-Li L, et al. (1997). Ultraviolet A irradiation up-regulates type VII collagen expression in human dermal fibroblasts. J Invest Dermatol 108: 125-8
12. Cicardi M, Zanichelli A. (2010). Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today 46: 867-74
13. De Souza M, Viswanathan M, inventors; Lotus Tissue Repair Inc., assignee. Collagen 7 and Related Methods. WO/2013/020064 (2013
14. Desnick RJ. (2004). Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27: 385-410
15. Fine JD, Bruckner-Tuderman L, Eady RA, et al. (2014). Inherited epidermolysis bullosa: Updated recommendation on diagnosis and classification. J Am Acad Dermatol 70: 1103-26
16. Fine JD, Eady RA, Bauer EA, et al. (2008). The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 58: 931-50
17. Fine JD, Johnson LB, Weiner M, et al. (2009). Epidermolysis bullosa and the risk of life-Threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol 60: 203-11
18. Fritsch A, Loeckermann S, Kern JS, et al. (2008). A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 118: 1669-79
19. Heinonen S, Mannikko M, Klement JF, et al. (1999). Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci 112: 3641-8
20. Jayapal KP, Wlaschin KF, Hu WS, et al. (2007). Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog 103: 40-7
21. Keene DR, Sakai LY, Lunstrum GP, et al. (1987). Type VII collagen forms an extended network of anchoring fibrils. J Cell Biol 104: 611-21
22. Kim JY, Kim YG, Lee GM. (2012). CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93: 917-30
23. Leader B, Baca QJ, Golan DE. (2008). Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Dis 7: 21-39
24. Lin AN, Carter DM. (1992). Epidermolysis Bullosa: Basic and Clinical Aspects. New York, NY: Springer
25. Lunstrum GP, Sakai LY, Keene DR, et al. (1986). Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils. J Biol Chem 261: 9042-8
26. Madoiwa S, Yamauchi T, Hakamata Y, et al. (2004). Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost 2: 754-62
27. Ortiz-Urda S, Thyagarajan B, Keene DR, et al. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-70
28. O'Keefe EJ, Chiu ML. (1988). Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth. J Invest Dermatol 90: 2-7
29. Pelkonen R, Kivirikko KI. (1970). Hydroxyprolinemia: an apparently harmless familial metabolic disorder. N Engl J Med 283: 451-6
30. Remington J, Wang X, Hou Y, et al. (2009). Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17: 26-33
31. Saelman EU, Nieuwenhuis HK, Hese KM, et al. (1994). Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood 83: 1244-50
32. Sakai LY, Keene DR. (1994). Fibrillin monomers and microfibrils In: Ruoslahti E, Engvall E (eds) Methods in Enzymology vol 245. Academic Press: New York, NY, 47-50
33. Sakai LY, Keene DR, Morris NP, et al. (1986). Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 103: 1577-86
34. Schiffmann R, Kopp JB, Austin HA III, et al. (2001). Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-9
35. Uitto J, Christiano AM. (1992). Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest 90: 687-92
36. Uitto J, Christiano AM. (1994). Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res 287: 16-22
37. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363: 629-39
38. Wong T, Gammon L, Liu L, et al. (2008). Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179-89
39. Woodley DT, Atha T, Huang Y, et al. (2004). Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 11: 318-26
40. Woodley DT, Bachmann PM, O'Keefe EJ. (1988). Laminin inhibits human keratinocyte migration. J Cell Physiol 136: 140-6
41. Woodley DT, Briggaman RA, O'Keefe EJ, et al. (1984). Identification of the skin basement membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310: 1007-13
42. Woodley DT, Hou YP, Martin S, et al. (2008). Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis. J Biol Chem 283: 17838-45
43. Woodley DT, Keene DR, Atha T, et al. (2004). Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10: 693-5
44. Woodley DT, Krueger GG, Jorgensen CM, et al. (2003). Normal and genecorrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121: 1021-8
45. Woodley DT, Remington J, Huang Y, et al. (2007). Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen and promote wound healing. Mol Ther 15: 628-35
46. Woodley DT, Wang X, Amir M, et al. (2013). Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol 133: 1910-3
47. Xu L, Gao C, Sands MS, et al. (2003). Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 101: 3924-32